Thiopurines and Risk of Colorectal Neoplasia in Patients With Inflammatory Bowel Disease: A Meta-analysis

Clinical Gastroenterology and Hepatology

Volumn 12, Issue 11, 2014, Pages 1793-1800.e1

  Jess, Tine ^a   Lopez, Anthony ^b   Andersson, Mikael ^a   Beaugerie, Laurent ^c   Peyrin Biroulet, Laurent ^b  

^a STATENS SERUM INSTITUT   (Denmark)

^b UNIVERSITY HOSPITAL OF NANCY   (France)

^c HÔPITAL SAINT ANTOINE   (France)

Author keywords

Azathioprine; Colon Cancer; Inflammation; Risk Factor

Indexed keywords

MERCAPTOPURINE; IMMUNOSUPPRESSIVE AGENT;

ARTICLE; CANCER RISK; COLORECTAL CANCER; COLORECTAL TUMOR; CROHN DISEASE; DIGESTIVE SYSTEM CANCER; DISEASE DURATION; HUMAN; INFLAMMATORY BOWEL DISEASE; META ANALYSIS; SENSITIVITY ANALYSIS; ULCERATIVE COLITIS; COLORECTAL NEOPLASMS; COMPLICATION; INFLAMMATORY BOWEL DISEASES; RISK ASSESSMENT; TREATMENT OUTCOME;

6-MERCAPTOPURINE; COLORECTAL NEOPLASMS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 84908245513     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2014.05.019     Document Type: Article

References (31)

1. Peyrin-Biroulet L., Lepage C., Jooste V., et al. Colorectal cancer in inflammatory bowel diseases: a population-based study (1976-2008). Inflamm Bowel Dis 2012, 18:2247-2251.
2. Jess T., Rungoe C., Peyrin-Biroulet L. Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol 2012, 10:639-645.
3. Jess T., Gamborg M., Matzen P., et al. Increased risk of intestinal cancer in Crohn's disease: a meta-analysis of population-based cohort studies. Am J Gastroenterol 2005, 100:2724-2729.
4. Jess T., Simonsen J., Jorgensen K.T., et al. Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years. Gastroenterology 2012, 143:375-381.
5. Soderlund S., Brandt L., Lapidus A., et al. Decreasing time-trends of colorectal cancer in a large cohort of patients with inflammatory bowel disease. Gastroenterology 2009, 136:1561-1567.
6. Rutter M., Saunders B., Wilkinson K., et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004, 126:451-459.
7. Ullman T.A., Itzkowitz S.H. Intestinal inflammation and cancer. Gastroenterology 2011, 140:1807-1816.
8. Dignass A., Lindsay J.O., Sturm A., et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. JCrohns Colitis 2012, 6:991-1030.
9. Dignass A., Van A.G., Lindsay J.O., et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: current management. JCrohns Colitis 2010, 4:28-62.
10. Van A.G., Dignass A., Panes J., et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. JCrohns Colitis 2010, 4:7-27.
11. Lichtenstein G.R., Hanauer S.B., Sandborn W.J. Management of Crohn's disease in adults. Am J Gastroenterol 2009, 104:465-483.
12. Kornbluth A., Sachar D.B. Ulcerative colitis practice guidelines inadults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2010, 105:501-523.
13. Nguyen G.C., Gulamhusein A., Bernstein C.N. 5-Aminosalicylic acid is not protective against colorectal cancer in inflammatory bowel disease: a meta-analysis of non-referral populations. Am J Gastroenterol 2012, 107:1298-1304.
14. Velayos F.S., Terdiman J.P., Walsh J.M. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol 2005, 100:1345-1353.
15. Beaugerie L., Svrcek M., Seksik P., et al. Risk of colorectal high-grade dysplasia and cancer in inflammatory bowel disease in the thiopurine era: a prospective study. Gastroenterology 2013, 145:166-175.
16. Pasternak B., Svanstrom H., Schmiegelow K., et al. Use of azathioprine and the risk of cancer in inflammatory bowel disease. Am J Epidemiol 2013, 177:1296-1305.
17. Fraser A.G., Orchard T.R., Robinson E.M., et al. Long-term risk ofmalignancy after treatment of inflammatory bowel diseasewith azathioprine. Aliment Pharmacol Ther 2002, 16:1225-1232.
18. Baars J.E., Looman C.W., Steyerberg E.W., et al. The risk of inflammatory bowel disease-related colorectal carcinoma is limited: results from a nationwide nested case-control study. Am J Gastroenterol 2011, 106:319-328.
19. Armstrong R.G., West J., Card T.R. Risk of cancer in inflammatory bowel disease treated with azathioprine: a UK population-based case-control study. Am J Gastroenterol 2010, 105:1604-1609.
20. van Schaik F.D., van Oijen M.G., Smeets H.M., et al. Thiopurines prevent advanced colorectal neoplasia in patients with inflammatory bowel disease. Gut 2012, 61:235-240.
21. Connell W.R., Kamm M.A., Dickson M., et al. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet 1994, 343:1249-1252.
22. Gupta R.B., Harpaz N., Itzkowitz S., et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology 2007, 133:1099-1105.
23. Matula S., Croog V., Itzkowitz S., et al. Chemoprevention of colorectal neoplasia in ulcerative colitis: the effect of 6-mercaptopurine. Clin Gastroenterol Hepatol 2005, 3:1015-1021.
24. Lashner B.A., Provencher K.S., Seidner D.L., et al. The effect of folic acid supplementation on the risk for cancer or dysplasia in ulcerative colitis. Gastroenterology 1997, 112:29-32.
25. Siegel C.A., Sands B.E. Risk factors for colorectal cancer in Crohn's colitis: a case-control study. Inflamm Bowel Dis 2006, 12:491-496.
26. Velayos F.S., Loftus E.V., Jess T., et al. Predictive and protective factors associated with colorectal cancer in ulcerative colitis: a case-control study. Gastroenterology 2006, 130:1941-1949.
27. Terdiman J.P., Steinbuch M., Blumentals W.A., et al. 5-Aminosalicylic acid therapy and the risk of colorectal cancer among patients with inflammatory bowel disease. Inflamm Bowel Dis 2007, 13:367-371.
28. Tang J., Sharif O., Pai C., et al. Mesalamine protects against colorectal cancer in inflammatory bowel disease. Dig Dis Sci 2010, 55:1696-1703.
29. Prentice R.L., Breslow N.E. Retrospective studies and failure-time models. Biometrics 1978, 65:153-158.
30. Herrinton L.J., Liu L., Fireman B., et al. Time trends in therapiesand outcomes for adult inflammatory bowel disease, Northern California, 1998-2005. Gastroenterology 2009, 137:502-511.
31. Rungoe C., Langholz E., Andersson M., et al. Changes in medical treatment and surgery rates in inflammatory bowel disease: a nationwide cohort study 1979-2011. Gut 2014, 63:1607-1616.